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aBsTRacT
INTRODUCTION: Around 75% of menopausal women experi-
ence hot flushes (HF) and 10-20% of all postmenopausal 
women find this very distressing. The aim of this study is  
to evaluate the efficacy of acupuncture on moderate-to- 
severe menopausal symptoms in general and HF in par-
ticular. 
METHODS: An un-blinded randomised trial (cross-over) with 
1:1 allocation to early (intervention) versus late (control)  
acupuncture. The included women suffer from moderate-
to-severe HF and will receive a weekly treatment during five 
consecutive weeks in the following predefined acupuncture 
points: CV-3, CV-4, LR-8, SP-6, SP-9. All acupuncturists will 
be medical doctors educated in acupuncture. The primary 
outcome is change in HF from baseline to week 6 measured 
by the HF scale from the MenoScores Questionnaire (MSQ). 
Secondary outcomes are change in other menopausal 
symptoms, in particular day and night sweats and meno-
pausal-specific sleeping problems, also measured by other 
scales from the MSQ. A total of 68 patients must be en-
rolled to detect a relevant clinical reduction on the above 
MSQ scales. Both intention-to-treat and per-protocol ana-
lyses will be conducted; four or more treatments are con-
sidered adequate adherence. 
CONCLUSIONS: In the ACOM study, we explore the potential 
benefits of acupuncture on moderate-to-severe meno-
pausal symptoms. The cross-over design offers the possi-
bility of examining the legacy effect of acupuncture. 
FUNDING: The Idella Foundation, the University of Copen-
hagen and the Research Foundation of General Practice. 
TRIAL REGISTRATION: Clinicaltrials NCT02746497.
Menopause is a normal condition that the majority of 
women experience in their early fifties [1]. Menopausal 
symptoms are commonly experienced for four to five 
years and for some women even longer [1-3]. Around 
75% of menopausal women experience hot flushes (HF) 
[2-4]; and 10-20% of all postmenopausal women find 
the HF very distressing [2]. Some menopausal women 
also experience night sweats, emotional vulnerability, 
sleep disturbances, fatigue, joint pain, cognitive chan-
ges, vaginal dryness and loss of sexual desire [1, 2, 5]. 
Hormone therapy (HT) has been an effective treat-
ment for menopausal symptoms for many years [6]. 
However, research has shown that long-term HT in-
creases the risk of breast cancer and thromboembolic 
disorders, among others [7]. Non-hormonal medication 
such as gabapentin, clonidine and antidepressants may 
reduce menopausal HF. However, these drugs have fre-
quent side effects, e.g. dizziness, fatigue, dry mouth, 
constipation and difficulty in sleeping [1, 2, 4, 8]. Other 
suggested remedies include relaxation, exercise and use 
of herbal remedies, but currently there is no convincing 
evidence of any beneficial effect [4, 9]. 
Acupuncture has been shown to be effective on 
menopausal HF in several studies [10, 11]. However, 
many of these studies have been criticised for method-
ological problems, e.g. poor study design, inadequate 
control group and individualised treatment (not using 
standardised acupuncture points) [10, 12]. Moreover, 
the studies have used different methods and outcome 
measures (some not validated) and overall comparison 
of the results is therefore difficult [10, 12]. Consequent-
ly, further research and better-designed randomised 
controlled studies are warranted [10, 12].
An estimate suggests that up to two-thirds of the 
Danish general practitioners (GPs) are using acupuncture 
on a regular basis [13]. This large proportion warrants 
that acupuncture for menopausal symptoms be con-
sidered for implementation in general practice, and any 
beneficial effect of acupuncture on menopausal symp-
toms may quickly find its way to menopausal women.
Hypothesis:Acupuncture can reduce moderate-to-
severe menopausal symptoms. Specifically, acupuncture 
may produce a clinically meaningful reduction of HF. 
Objective: To evaluate the efficacy of a standard-
ised acupuncture approach on women suffering from 
moderate-to-severe menopausal symptoms; primarily 
the efficacy on HF measured as change from baseline to 
week 6.
mEThOds
This is a randomised trial (cross-over) with 1:1 allocation 
to early (intervention) versus late (control) acupuncture. 
The reporting will follow the STandards for Reporting  
Interventions in Clinical Trials of Acupuncture (STRICTA) 
[14]. The protocol adheres to the SPIRIT 2013 state-
ment; further details are found in the Appendix [15]. 
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Recruitment
The study subjects will primarily be recruited through 
GPs, GPs/medical doctors who are members of the Dan-
ish Society for Evidence-based Acupuncture (DSEA) or 
the Danish Medical Acupuncture Society (DMAS), groups 
for menopausal women on the social media and local 
newspapers. 
study subjects
The inclusion and exclusion criteria are presented in  
Table 1.
screening and informed consent
Potential study subjects will be screened based on the 
validated HF scale from the MenoScores Questionnaire 
(MSQ). Included study subjects will have a score of 4 
(quite a bit) or above 4 (a lot) on the HF scale. Study sub-
jects will receive oral and written information and must 
sign an informed consent form before enrolment. 
Baseline
In a baseline questionnaire, information will be obtained 
about age, marital status, children living at home, edu-
cation level, gynaecological and obstetric history, urinary 
incontinence, comorbidity, use of medication, use of al-
ternative treatment, previous use of acupuncture or al-
ternative treatment, exercise, alcohol consumption and 
smoking status. Moreover, MSQ must be completed at 
baseline (week 0). Thereafter, the study subjects will be 
randomised.
Randomisation
The allocation sequence is generated using the com-
puter software SAS (version 9.4, SAS Institute, Cary, NC, 
USA). Study subjects are allocated to one of the two ran-
domisation groups, Group E (early intervention) and 
Group L (late intervention) by an independent person 
(independent of the project organisation). Randomisa-
tion is done in blocks, stratified by age and level of 
symptoms (“quite a bit” or “a lot” HF) using random 
block sizes. 
intervention and settings
The study will take place in Danish medical clinics. All 
study subjects will be offered a weekly treatment during 
five consecutive weeks. In study weeks 1-5, Group E will 
receive treatment and Group L will act as a control 
group. After study week 5, the groups trade places: 
Group L will then receive treatment for five weeks (trial 
week 6-10) and Group E will act as a follow-up group 
(Table 2).
The acupuncture style used will be Western Medical 
Acupuncture (WMA) with standardised treatment in 
predefined points. In WMA theory, acupuncture acts 
mainly by simulating the nervous system. The classic  
acupuncture points may be the best sites to needle, but 
not the only place to stimulate the nervous system; and 
sham acupuncture is rather perceived as another, but 
less effective form of therapeutic needling than an inert 
(placebo) treatment [16, 17]. Moreover, earlier studies 
have shown that sham acupuncture is associated with a 
aBBREviaTiOns
ABD = abdominal symptoms
DMAS = Danish Medical Acupuncture Society
DNS = day and night sweats
DSEA = Danish Society for Evidence-based Acupuncture
EM = emotional symptoms
GP = general practitioner
GS = general sweating
HF = hot flushes
HT = hormone therapy
MEM = memory changes
MSQ = MenoScores Questionnaire
MSSP = menopausal specific sleeping problems
PHY = physical symptoms
SEX = sexual symptoms
SH = skin and hair symptoms
URIN = urinary and vaginal symptoms
WMA = Western Medical Acupuncture  
TaBlE 1
Inclusion and exclusion criteria.
Inclusion criteria
Woman
Age 40-65 yrs
“Quite a bit” or “a lot” bothered by hot flushes: score ≥ 4 on a validated scale measuring hot flushes, 
MenoScores questionnaire
No conflicts of interests and have provided informed consent
Have an e-mail address
Exclusion criteria
Hysterectomized and/or bilateral oophorectomized
Systemic hormone therapy for menopausal symptoms within the past 4 weeks
Hormonal intrauterine device within the past 4 weeks
Treatment with antidepressants and/or antiepileptics within the past 4 weeks
Other medical treatment for hot flushes, e.g. clonidine, within the past 4 weeks
Other herbal remedies/alternative treatment for menopausal symptoms, e.g. Black Cohosh,  
Red Clover, Evening Primrose oil, Melbrosia, within the past 4 weeks
Alcohol consumption exceeding 21 drinks per week
Using prescribed sleeping pills and/or prescribed sedatives 
Treatment with corticosteroids within the past 4 weeks, inhaled steroids not excluded
Previously diagnosed with breast cancer, endometrial cancer, cervical cancer or ovarian cancer
Diagnosed with other severe cancer disease within the past 5 yrs
Heart valve disease
Insulin dependent and/or poorly controlled diabetes mellitus
Diagnosed with thyroid disease
Under investigation for serious disease e.g. cancer
Pregnancy or breast-feeding within the past 2 yrs
Received acupuncture treatment within the past 6 mo.s
Participating in another trial or participated in another trial in the past 2 weeks before screening
Dan Med J 64/3  March 2017 da n i s h m E d i c a l J O U R n a l   3
moderately large non-specific effect that might be larger 
than other inert placebo interventions [18]. Thus, in this 
study we use a control group rather than a placebo 
group.
acupuncturists
Acupuncturists must be medical doctors educated in  
acupuncture by the DSEA, the DMAS or similar. An infor-
mation meeting will be held with the acupuncturists and 
all are offered a two and a half-hour course concerning 
the study design and a review of the selected acupunc-
ture points and techniques. The acupuncturists are  
instructed to give the acupuncture treatment and to 
provide no other treatment or counselling. The acupunc-
turists will receive a manual with instructions, including 
an overview of the specific acupuncture points. We ex-
pect that the study will include ten acupuncturists. 
needle information
The needles will be sterile disposable needles (Plandent) 
size 0.30 × 30 mm. The needles will be inserted perpen-
dicularly and rotated manually between index finger and 
thumb for a few seconds to elicit “de-qi” (needle sensa-
tion). The needle retention time will be ten minutes.  
Afterwards, the needle will be removed.
acupuncture points
The acupuncture points (CV-3, CV-4, LR-8, SP-6, SP-9) 
[19] are listed in Table 3. In total, 8 points are used as 
LR-8, SP-6 and SP-9 are given bilaterally. 
Outcome
Outcomes will be evaluated using the MSQ. This ques-
tionnaire was developed and validated based on a litera-
ture review, two focus groups, four single interviews, 
four pilot tests and a cross-sectional validation study in-
cluding 1,504 women’s completion of a draft version of 
the questionnaire. Data collected for this validation 
study were analysed using item response theory Rasch 
models. The MSQ encompasses 11 scales and one single 
item, measuring different dimensions of menopausal 
symptoms. The scale score refers to the sum of the 
scores of the items in the scale. Table 4 presents the 
MSQ scales.
TaBlE 2
Trial flow and time schedule: enrolment, interventions and assessments.
study period
Enrolment, 
time –t1
allocation, 
time 0 W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 W26
Enrolment
Eligibility screen x
Informed consent x
Screening questionnaire x
Allocation x
Intervention
Group E x x x x x
Group L x x x x x
Assessmentc
Screening questionnaire incl. HF scale x
Baseline data x
MSQ xa x xb x x X
HF scale = hot flushes scale from MSQ; MSQ = MenoScores Questionnaire; Wx = study week no. x.  
a) MSQ is completed before allocation and 1st treatment. 
b) Group E completed MSQ 1 week after final treatment (week 6), Group L completed MSQ before 1st treatment (week 6). 
c) Intermediate assessment at week 3, main comparison of primary outcome at week 6 before cross-over, assessment of legacy effect at week 11, assessment of long-term effect at 
week 26.
post-allocation long-term
TaBlE 3
Acupuncture points and location.
Point location
CV-3
Anterior midline, 1 cun proximal to the symphysis 
Insertion depth: perpendicularly 0.5-1 cm
CV-4 Anterior midline, 1 cun proximal to CV-3 and 3 cun inferior to the umbilicus 
Insertion depth: perpendicularly 0.5-1 cm
LR-8
Medial side of the knee, in the depression anterior/medial to the tendons of semim-
embranosus and the semitendinosus muscles, at the medial end of the popliteal crease 
Insertion depth: perpendicularly 1.5-2 cm
SP-9 Under the medial condyle of tibia in a depression between the posterior tibia and  
m. gastrocnemius 
Insertion depth: perpendicularly 2-3 cm
SP-6
3 cun proximal to the prominent part of the medial malleoli, on the medial and posterior 
border of the tibia 
Insertion depth: perpendicularly 1-3 cm
Cun = an acupuncture measurement unit, 1 cun corresponds to the width of the study subject’s thumb.
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All study subjects will receive the MSQ by e-mail in 
study weeks 0, 3, 6, 8, 11 and 26 and are asked to com-
plete the MSQ within 1-2 days. The MSQ is completed 
electronically. Study subjects not returning a completed 
questionnaire within the scheduled time will receive a 
reminder within 1-2 days. When receiving the planned 
acupuncture treatment, the MSQ must be completed 
one or two days before the third treatment and one 
week after the fifth (the last) treatment (Table 2). 
Primary outcome
Primary outcome is change in HF means from baseline 
to week 6 expressed by a score on the HF scale from the 
MSQ. The HF scale consists of two items with four re-
sponse categories (no, a bit, quite a bit, a lot); and the 
range of score is 0 to 6, where six expresses “a lot” HF 
and nobody expresses “no” HF. 
Secondary outcome
The secondary outcomes are change from baseline in 
the remaining MSQ scales covering the following do-
mains: day and night sweats (DNS), general sweating 
(GS), menopausal specific sleeping problems (MSSP), 
emotional symptoms (EM), memory changes (MEM), 
skin and hair symptoms (SH), physical symptoms (PHY), 
abdominal symptoms (ABD), urinary and vaginal symp-
toms (URIN), sexual symptoms (SEX) and a single item 
about tiredness. While the scales have different ranges 
(Table 4), they all have a minimum of 0 denoting no 
symptoms; and for each of these scales higher scores  
express more symptoms. After the final acupuncture 
treatment, the study subjects are asked to evaluate the 
overall effect of their acupuncture treatments along 
with completing the MSQ at week 6 (Group E) or week 
11 (Group L). At week 11, all study subjects are also 
asked if during the study period and despite recommen-
dations, they have used any other treatment for meno-
pausal symptoms. Finally, when completing the MSQ  
in week 26, the study subjects are asked if they have 
started any treatment for menopausal symptoms after 
ending the study in week 11. Drop-outs will be con-
tacted in order to clarify the causes of drop-out. 
Power calculations 
The power calculation was based on data from the MSQ 
validation study. We used the primary outcome HF and 
the two secondary outcomes DNS and MSSP to establish 
the sample size. A reduction in a scale score correspond-
ing to a reduction from “a lot” to “quite a bit” on a  
global item about whether the respondent was both-
ered by menopausal symptoms was considered a clin-
ically relevant reduction. Women who were “a lot” both-
TaBlE 4
Outcome evaluated by the MenoScores Questionnaire (MSQ) scalesa.
msQ
scale single item msQ + 1 item items, n scale score
Outcome
Primary Hot flushes   2 0-6
Secondary Day and night sweats   2 0-6
General sweating   2 0-6
Menopausal specific sleeping problems   2 0-6
Emotional symptoms 12 0-36
Memory changes   2 0-6
Skin and hair symptoms   8 0-16
Physical symptoms   8 0-24
Abdominal symptoms   4 0-8
Urinary and vaginal symptoms   4 0-12
Sexual symptoms   4 0-8
About  
tiredness
  1 0-3
Enquiring
After last acupuncture  
treatment
About the overall effect
Week 11 About use of other treatments for  
menopausal symptoms
Asking
Week 26
If the study subject has started any treatment 
for menopausal symptoms after week 11
a) 11 scales and 1 single item, 51 items in total.
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ered by menopausal symptoms scored a mean of 4.98 
on the HF scale, and women who were “quite a bit” 
bothered scored a mean of 3.48 on the HF scale; both 
groups with a standard deviation (SD) around 1.4. To de-
tect this reduction at 90% power, 5% level of signifi-
cance, and accounting for 20% dropouts, 40 + 8 = 48 
study subjects need to be included; 24 study subjects in 
each group. To detect a similar reduction in DNS and 
MSSP, a total number of 56 and 68 study subjects, re-
spectively, need to be included (including dropouts). 
Hence, we aim to include a total of 68 study subjects in 
the ACOM study.  
statistical analysis
Outcomes will be analysed in linear mixed models in-
cluding a subject-random effect so as to adjust for re-
peated measurements on the same individual. The main 
comparisons will be the mean difference in the out-
comes between the randomisation groups from baseline 
to week 6, assessed by Wald tests. Outcomes in week 11 
express the legacy effect and outcomes in week 26 ex-
press any longer-lasting effect.
The analyses will be adjusted for age and level of 
symptoms so as to account for the stratification in the 
randomisation procedure. Comparisons of the outcomes 
at baseline will be done along with the outcome analy-
ses in the linear models to assess the randomisation. 
Additionally to this aim, covariates at baseline will be 
compared between randomisation groups with t-tests 
(continuous covariates) or chi-squared tests (categorical 
covariates). A logistic regression model will be used to 
investigate whether there are factors that influence 
dropout; these factors will then be added as adjust-
ments to the linear mixed models in additional analyses 
so as to account for any attrition.
The primary analyses will be intention-to-treat ana-
lyses. Additionally, per-protocol analyses will be con-
ducted in which non-compliers will be omitted; four or 
more treatments are considered adequate adherence.  
A p-value < 0.05 will be considered significant. The stat-
istical significance for the secondary outcomes will be 
assessed with a false discovery rate of 5%. SAS v9.4 will 
be used for the analyses.
Blinding
The statisticians and outcome assessors will be blinded 
until all analyses have been completed. Study subjects 
and acupuncturists cannot be blinded.
adverse events
We expect no risk for the study subjects. Adverse events 
are expected to be minimal and may be bruises or irrita-
tion at the needle-insertion site and for few study sub-
jects transient fatigue, pruritus, nausea or briefly inten-
sified symptoms following treatment. Along with 
completing the MSQ at weeks 3, 6, 8, 11 and 26, the 
study subjects are asked about adverse events in rela-
tion to the treatments. Adverse events will be presented 
along with the outcomes.
Ethics, regulatory authorities and registration 
Approvals from the Committees on Health Research  
Ethics (H-16016365), the Committee of Multipractice 
Studies in General Practice (MPU 08-2016) and the Dan-
ish Data Protection Agency (SUND-2016-24) are ob-
tained. The study will be conducted in accordance with 
the Declaration of Helsinki. 
Trial registration: clinicaltrials.gov (NCT02746497).
discUssiOn
Earlier studies have shown effect of acupuncture on 
menopausal HF. Unfortunately, these studies have 
methodological deficiencies and the quality of the evi-
dence is generally low [10, 12]. If sham acupuncture is 
not inert, a comparison of acupuncture with sham acu-
puncture is more likely a comparison of two different 
types of acupuncture, and claiming that such a study is a 
placebo-controlled study would be incorrect. At the pre-
sent time, no proper acupuncture placebo comparator 
exists [16-18] and blinding is obviously difficult. Both of 
these issues constitute limitations in acupuncture  
studies, this study included. However, a strength in our 
study is the use of a control group to demonstrate the 
different impact of acupuncture treatment versus no 
treatment. Moreover, our statisticians and outcome as-
sessors will be blinded until all analyses have been com-
pleted.
Acupuncture  
needle in SP-6.
 6  da n i s h m E d i c a l J O U R n a l Dan Med J 64/3  March 2017
A specific strength of this study is the use of a vali-
dated and reliable outcome measure (the MSQ) with 
high content validity and adequate psychometric prop-
erties. The MSQ was developed and validated in an ear-
lier validation study, and data from this validation study 
were used to generate a power calculation for this study. 
This study will use a standardised intervention in 
the same predefined acupuncture points. Individualised 
tailored treatment might be closer to a real clinical set-
ting and could be more effective than standardised 
treatment, but when testing a specific treatment in a 
scientific trial, aiming for high applicability of findings, 
we believe that the treatment should be standardised. 
Furthermore, as an attempt to avoid that other inter-
ventions affect the results, we exclude all subjects who 
are included in other studies or are using other inter-
ventions against menopausal symptoms. Finally, the 
cross-over design makes it possible to survey a potential 
legacy effect in group E and may improve the adherence 
of the control group L since they will be also offered  
acupuncture.
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